HIV PrEP Video Perspectives

Healio spoke with David Wohl, MD, about prescribing, managing and discussing HIV pre-exposure prophylaxis.

In this video series, Wohl, professor of medicine at University of North Carolina Chapel Hill and site leader of the HIV Prevention and Treatment Clinical Trials Unit at Chapel Hill, discussed:

• the rarity of side effects with the use of HIV PrEP;
• PrEP persistence, and how “people’s risk change”;
• what to consider when prescribing PrEP to patients;
• the risks and benefits of both emtricitabine and tenofovir disoproxil fumarate (Truvada, Gilead) and emtricitabine and tenofovir alafenamide (Descovy, Gilead);
• reduced creatinine clearance and risk for developing renal complications associated with HIV PrEP use; and
• various areas of unmet need for patients who require HIV PrEP.

Disclosure:

Wohl receiving research funding to his institution from AbbVie, Gilead Sciences and Merck, serving on advisory boards for Gilead Sciences, Janssen, Merck and ViiV Healthcare; and serving as a consultant for Gilead Sciences and ViiV Healthcare.